论文部分内容阅读
11月29日,美国FDA宣布:生产滴眼液等OTC 产品的生产商MBI销售股份有限公司,又称分子生物制品公司,已签署一份同意书,该同意书要求该公司停止生产和销售药物,直至它纠正其在加利福尼亚 Benicia工厂的生产问题和其他违规行为为止。MBI的产品线包括商品名为Oxydrops、Bright Eyes、Bright EyesⅡ、Clarity Vision for Life、Visitein和Can-C 等滴眼液的产品和几种OTC止痛产品的销售。更多信息请参见:http://www．fda．gov/bbs/topics/NEWS/ 2005/NEW01265．html。
On November 29, the U.S. FDA announced that MBI Sales Co., Ltd., also known as Molecular Biotech, a manufacturer of OTC products such as eye drops, has signed a letter of consent which requires the company to stop producing and selling drugs Until it corrected its production problems at Benicia, California, and other irregularities. MBI’s product lines include the sale of eye drops such as Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein and Can-C and several OTC analgesics. For more information, see: http: // www. fda. gov / bbs / topics / NEWS / 2005 / NEW01265. html